An essential checklist for cognitive longevity — filled with specific exercise, heat stress, and omega-3 protocols for boosting BDNF. Enter your email, and we'll deliver it straight to your inbox.
The scientific study of psychedelic drugs has occurred in fits and starts over the past several decades, but it has experienced a revival in recent years, with emphasis on the drugs' beneficial effects on depression and other neuropsychiatric illnesses. Psilocybin, in particular, has emerged as a potent psychedelic drug that shows promise as a treatment for depression, offering a paradigm shift from traditional therapeutic approaches.
Psilocybin is a psychoactive compound derived from certain types of mushrooms – often referred to as "magic mushrooms" or "shrooms." The compound elicits an array of psychedelic effects on the human brain, including auditory and visual hallucinations that arise from reduced activity in the thalamus, an area of the brain that processes sensory input.
"These people experience very large and sustained decreases in anxiety and depression, and the effects occurred quite promptly after the administration of the drug."- Roland Griffiths, Ph.D. Click To Tweet
Recent clinical trials have demonstrated that psilocybin, when administered in conjunction with psychotherapy, helped people with depression achieve remission of their depressive symptoms – an effect that lasted for at least one month post-treatment. Scientists aren't sure just how psilocybin works to relieve depression, but research in rodents suggests that the compound fosters the formation of new, lasting connections in the brain, bolstering synapse density. This is important because people with depression often have low synapse density.
"This isn't a guided session. There are two people present who…are there just for safety purposes and to make people feel that if anxiety or fear arises, they can be reassured." - Roland Griffiths, Ph.D. Click To Tweet
An important aspect of studying potent hallucinogenic drugs like psilocybin is understanding and respecting the risks they carry to study participants. Dr. Roland Griffiths, a professor of psychiatry at the Johns Hopkins University School of Medicine and one of the world's leading experts on psychedelics, was instrumental in developing a study protocol for safely and ethically investigating the compounds' effects.
This episode was fiscally sponsored through The Film Collaborative and a grant from a generous anonymous donor.
In the segment featuring the conversation with Dr. Griffiths, he explains that adherence to this protocol, which involves close participant monitoring, a dose methodically determined to reduce the likelihood of a challenging experience while maximizing therapeutic effects, and the provision of a safe physical environment and interpersonal support, is crucial for participant safety. An added bonus: It also safeguards the capacity to conduct future research.
With research on psilocybin still in its infancy, it's difficult to say whether the compound will one day become a standard intervention for depression. But the emerging findings look promising, offering hope for the millions of people worldwide who live with the condition.
A naturally occurring psychedelic compound produced by more than 200 species of mushrooms. As a prodrug, psilocybin is quickly converted by the body to psilocin, which has mind-altering effects including euphoria, visual and mental hallucinations, changes in perception, a distorted sense of time, and spiritual experiences, and can include possible adverse reactions such as nausea and panic attacks.
A class of hallucinogenic substances whose primary action is to alter cognition and perception, typically as serotonin receptor agonists, causing thought and visual/auditory changes, and "heightened state of consciousness." Major psychedelic drugs include mescaline, LSD, psilocybin, and DMT. Psychedelics have a long history of traditional use in medicine and religion, for their perceived ability to promote physical and mental healing.
A class of drugs that are typically used as antidepressants in the treatment of major depressive disorder and anxiety disorders. Some of the drugs that fall under this classification include: Citalopram (Celexa), Escitalopram (Lexapro), Fluoxetine (Prozac), Paroxetine (Paxil, Pexeva), Sertraline (Zoloft).
Listen in on our regularly curated interview segments called "Aliquots" released every week on our premium podcast The Aliquot. Aliquots come in two flavors: features and mashups.